Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMPION in Osteoarthritis of the Knee
NCT02556710Phase 3Completed
- Sponsor
- Ampio Pharmaceuticals, Inc.
- Start
- Sep 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aspartyl-alanyl-diketopiperazine in knee osteoarthritis (OA), sponsored by Ampio Pharmaceuticals, Inc. Primary endpoint: Western Ontario and McMaster Universities Osteoarthritis Index Pain Subscale at 12 weeks. Started Sep 2015; status: completed.
02
Drugs
aspartyl-alanyl-diketopiperazine
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02556710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02556710.